首页> 外文期刊>Expert review of cardiovascular therapy >Microvolt T-wave alternans testing for ventricular arrhythmia risk stratification.
【24h】

Microvolt T-wave alternans testing for ventricular arrhythmia risk stratification.

机译:室速心律失常的微伏T波交替疗法检测风险分层。

获取原文
获取原文并翻译 | 示例
           

摘要

Extensive research and clinical interest has focused recently on use of microvolt T-wave alternans (MTWA) as a means for sudden death risk stratification in patients with cardiomyopathy. Emphasis has been placed on determining whether MTWA testing can more accurately identify high-risk patients from the broad population who are potentially eligible for prophylactic implantable cardioverter defibrillators. More recent studies seek to determine if additional patients not currently covered by primary prevention implantable cardioverter defibrillator guidelines could be defined using MTWA. Unfortunately, accumulation of clinical data has not necessarily led to clarity in the minds of the end-users as to the role of MTWA in clinical practice. This article serves to provide background information, selective review of relevant studies, and a perspective on where the field stands today. A general framework for incorporating MTWA into clinical practice is presented.
机译:最近,广泛的研究和临床兴趣集中在使用微伏T波交替蛋白(MTWA)作为心肌病患者突然死亡风险分层的方法上。重点放在确定MTWA测试是否可以更准确地从广泛人群中识别出可能有资格使用预防性植入式心脏复律除颤器的高危患者。最近的研究试图确定是否可以使用MTWA来确定当前未被一级预防性植入式心脏复律除颤器指南覆盖的其他患者。不幸的是,临床数据的积累并不一定会导致最终用户清楚MTWA在临床实践中的作用。本文旨在提供背景信息,对相关研究的选择性综述以及对当今该领域现状的看法。提出了将MTWA纳入临床实践的一般框架。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号